Broad Spectrum CoV Therapeutic; rhACE2 Immunoadhesin to treat COVID19

Over the last decade, multiple pandemic events have highlighted the vulnerability of the world to existing and emerging infectious threats. Currently, COVID19 has infected >4M people resulting in >300K deaths. Although there are candidate drugs in development, the projected term until an effective COVID therapy or vaccine is available is projected to between 1-2 years. COVID19 marks the third coronavirus outbreak (preceded by SARS and MERS) within the last 20 years and suggests spillover of animal to human coronavirus will occur again.

Advancement of Hyperimmune candidates against select pathogens from the Antibody Therapeutics Business Unit’s Lead Generation Program

At Emergent BioSolutions our vision is to "Protect and Enhance Life". The Antibody Therapeutics Business Unit focuses on applying immunotherapies to prevent and treat human infectious diseases. This includes finding effective strategies to meet existing and emerging threats to public health and intentional biothreats. As part of these efforts the Lead Generation Program was created to address bacterial, viral and fungal pathogens.